Clinical Trial Update: Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating efficacy and safety of SAR153191 (REGN88) in patients with ankylosing spondylitis has completed and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• SAR153191 (REGN88) (SAR153191)

Snippet

Sponsor: Sanofi | Conditions: Ankylosing Spondylitis | Phase 2 | Status: COMPLETED | Results posted: 2017-08-08